hy genesis b - wecan - pitch 160303
TRANSCRIPT
Proprietary Technologiesthat reduce
Community Acquired Infections
Infection Control System
(248) 342-8040
Bob Gillow [email protected]
(248) 379-4638
Hospital Acquired Infections
Sources: CDC’s National Nosocomial Infection Survey (NNIS), New England Journal of Medicine, Journal of the American Medical Association, Infection Control Today
Healthcare Acquired Infections: (HAI)4% of Admissions100,000+ Deaths/year$43,000/Incident Expense$147+Billion National Expense
Antibiotic Resistant Strains:MRSA (1 of 3)VRECRE
The Problem – Short-lived Technologies
MRSA
Long-lasting Antimicrobial
• Mechanical Killing Mechanism• Broad Spectrum / Non-Selective• Cannot Genetically Adapt
Virus
Pathogens
Germs
Mold
The Solution…
Hand Armor (FDA Registered) - Hours of Protection
Long-lasting anti-microbial protection!
Surface Armor - Months of Protection
-Textile Armor 30+ Wash Cycles
Intellectual Property
Trade Secret – Considerations Patents are easy to copy
What is Unique? The HyGenesis Ingredients & Formulation
Process What we use How it is formulated/mixed
Head Start to Market From Concept to Market = 2+Years
Technology Validation
Henry Ford Health Systems- American Journal of Infection Control (Peer Review)
U of M – School of Public Health- Xi Wu, Ph.D, Alex Ricard, Ph.D- Letters in Applied Microbiology (Submitted)
Beaumont/OU School of Medicine (In Process)- Dwayne Baxa, Ph.D- BCBS Study
Customer Studies
HFHS – Infectious Disease Research
0
1
2
3
4
5
6
7
8
9
10
0 20 40 60 80 100
Num
ber o
f iso
late
s
Day
control test
Source: Henry Ford Infectious Disease Research Laboratory – Dr. D. Baxa
Kill Time – U of M Study
Long-term Kill – U of M Study
Ambulatory Care – 4+ Years
Hand Studies
• 2010 Study*• Study 1: Non-Alcohol vs. Alcohol Based
• 769 students (ages 5-12)• 33% decrease in absences
• Double blind, placebo controlled study
• Study 2: Non-Alcohol vs. At-will Hand Washing
• 420 students vs. alcohol based hand sanitizers• 41.9% decrease in absences
• 31.7% decrease in gastrointestinal illnesses• 44.2% decrease in respiratory-related
illnesses
* Dr. Shiyou Li, Cancer Research Professor, University of Texas
Hand Sanitizer Market
Global Industry Analysts, Inc. 2015
US Market
Competitive AdvantageKills 99.9
%
Long-Lastin
gHydro-phobic
Sooth Odor Cost Cost/
App.Cost/Day
Alcohol 11 .02 .86
Hand Armo
r.05 .10
Competitive AdvantageKills 99.9
%
Long-Lastin
gHydro-phobic
Sooth Odor Cost Cost/
App.Cost/Day
Alcohol 11 .02 .86
Hand Armo
r.05 .10
Competitors Cost/App.Goldshield .04
Qore24 .05Prefense .07fiteBac .10
PureBioguard .10Skin Guard 24 .23
Target Markets
Ambulatory Care
Ambulatory Care:• Out patient clinics• Physician Offices• Dental Offices• Chiropractor Offices• Urgent Care Centers• Surgery Centers• Public Health Clinics• Imaging Centers• Oncology Clinics• Dialysis Centers• Behavioral Health Clinics• Physical Therapy• Rehabilitation Centers• Adult Day Care
Channels Partners Markets 2016 2020
Resellers Ambulatory Care $60-200K $7M
VARs & Ambulatory Care $40-250K $21M
Direct HNI/HNV Ambulatory Care $52-100K $3M
Distributors
Federal &Commercial
$100-400K $12M
WEB Consumer $30-150K $2M
Private Label BacDefense Consumer $30-60K $4M
Go to Market - Channel Strategy
GLOBAL NUTRITION
$312K-1,160M
$49M
Brian Whitney, Inc.
Milestones
10th Channel Partner
20182016 2020
90th Channel PartnerSurface Armor
BCBS Study
1st Hospital Textile Armor
Scale-up!
Management Team
Bob Gillow – Founder/CEO (University of Michigan)– Hospital Computer Center– American Hospital Supply Corporation– Alamance Knit Fabrics– Military Veteran
Rob Kosnik – Founder/COO (Albion BA, MSU MBA)
– Multi-Channel Sales & Distribution– NASDAQ, SVP Sales & Marketing Catuity
Five Year Plan (000)Income 2016 2017 2018 2019 2020
Sales 312 810 2,430 9,720 48,600COGS 125 324 972 3,888 19,440
Gross Profit 187 486 1,458 5,832 29,160
ExpenseMarketing 90 150 300 600 1,200
Sales Comp. 70 100 200 500 950G & A 76 222 525 1,897 2,807
FDA/EPA 75 4 4 4 4Total 311 476 1,029 3,001 4,961
Net -124 10 429 2,831 24,199
Exit = Merger / Acquisition
Funding Request - $350,000
$312KPositive Cash Flow
Month
“Works Better / Costs Less”
Infection Control Solutions
(248) 342-8040
Bob Gillow [email protected]
(248) 379-4638
U of M Study - Video The Treated Surface - 10% dilution of Hand Armor prior to challenge.
Both membranes were challenged with Staph.
Study: Co-funded by MEDC
Scale: 30um (micro meters)
Untreated Surface: Treated Surface:
Viable Pathogens Dead Pathogens
Germs - Everwhere44% – Patient Surroundings
22% – After Touching Patient
21% – Before Touching Patient
8% – Before Aseptic Procedure
5% – After Bodily Fluids